References
- Barker DJ, Morris JA, Margetts BM. Diet and renal stones in 72 areas in England and Wales. Br J Urol. 1988; 62:315-8.319135410.1111/j.1464-410X.1988.tb04355.x
- Muslumanoglu AY, Binbay M, Yuruk E, Akman T, Tepeler A, Esen T, et al. Updated epidemiologic study of urolithiasis in Turkey. I: Changing characteristics of urolithiasis. Urol Res. 2011; 39:309-14.2116164610.1007/s00240-010-0346-6
- Seitz C, Fajkovic H. Epidemiological gender-specific aspects in urolithiasis. World J Urol. 2013; 31:1087-92.10.1007/s00345-013-1140-123942884
- Yanagawa M, Kawamura J, Onishi T, Soga N, Kameda K, Sriboonlue P, et al. Incidence of urolithiasis in northeast Thailand. Int J Urol. 1997; 4:537-40.10.1111/j.1442-2042.1997.tb00304.x9477179
- Sritippayawan S, Borvornpadungkitti S, Paemanee A, Predanon C, Susaengrat W, Chuawattana D, et al. Evidence suggesting a genetic contribution to kidney stone in northeastern Thai population. Urol Res. 2009; 37:141-6.1938762710.1007/s00240-009-0189-1
- Stitchantrakul W, Kochakarn W, Ruangraksa C, Domrongkitchaiporn S. Urinary risk factors for recurrent calcium stone formation in Thai stone formers. J Med Assoc Thai. 2007; 90:688-98.17487123
- Chen S, Gao X, Sun Y, Xu C, Wang L, Zhou T. Analysis of HK-2 cells exposed to oxalate and calcium oxalate crystals: proteomic insights into the molecular mechanisms of renal injury and stone formation. Urol Res. 2010; 38:7-15.10.1007/s00240-009-0226-019862510
- Aminian M, Nabatchian F, Vaisi-Raygani A, Torabi M. Mechanism of Coomassie Brilliant Blue G-250 binding to cetyltrimethylammonium bromide: an interference with the Bradford assay. Anal Biochem. 2013; 434: 287-91.2321956510.1016/j.ab.2012.11.014
- Wenrich BR, Trumbo TA. Interaction of nucleic acids with Coomassie Blue G-250 in the Bradford assay. Anal Biochem. 2012; 428:93-5.10.1016/j.ab.2012.06.01422743308
- Fu S, Sun Y, Luo L, Ye P. Relationship of arterial compliance and blood pressure with microalbuminuria and mildly decreased glomerular filtration rate: a Chinese community-based analysis. PloS one. 2014; 9:e101013.10.1371/journal.pone.010101324963717
- Triki S, Fekih O, Hellara I, Neffati F, Douki W, Hamda KB, et al. Association between serum cystatin C levels and cardiovascular disease in type 2 diabetic patients. Ann Bio Clin. 2013; 71:438-42.
- Somparn P, Hirankarn N, Leelahavanichkul A, Khovidhunkit W, Thongboonkerd V, Avihingsanon Y. Urinary proteomics revealed prostaglandin H D-2 isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis. J Proteomics. 2012; 75: 3240-7.10.1016/j.jprot.2012.03.034
- Mishra S, Sinha L, Ganesamoni R, Ganpule A, Sabnis RB, Desai M. Renal deterioration index: preoperative prognostic model for renal functional outcome after treatment of bilateral obstructive urolithiasis in patients with chronic kidney disease. J Endo. 2013; 27:1405-10.
- Schwille PO, Schmiedl A, Manoharan M, Wipplinger J. Idiopathic Recurrent Calcium Urolithiasis (IRCU): pathophysiology evaluated in light of oxidative metabolism, without and with variation of several biomarkers in fasting urine and plasma—a comparison of stone-free and -bearing male patients, emphasizing mineral, acid-base, blood pressure and protein status. Eur J Med Res. 2011; 16:349-66.21813378
- Arrabal-Polo MA, Arrabal-Martin M, Giron-Prieto MS, Orgaz-Molina J, Quesada-Charneco M, Lopez-Ruiz A, et al. Association of severe calcium lithogenic activity and bone remodeling markers. Urol. 2013; 82:16-21.10.1016/j.urology.2013.02.035
- Salama RH, Alghasham A, Mostafa MS, El-Moniem AE. Bone morphogenetic protein-2 will be a novel biochemical marker in urinary tract infections and stone formation. Clin Biochem. 2012; 45:766-9.10.1016/j.clinbiochem.2012.04.005
- Tsuji H, Tohru U, Hirotsugu U, Masanori I, Yuji H, Takashi K. Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation. Int J Urol. 2007; 14:630-4.10.1111/j.1442-2042.2007.01783.x17645608
- Mushtaq S, Siddiqui AA, Naqvi ZA, Rattani A, Talati J, Palmberg C, et al. Identification of myeloperoxidase, α-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta. 2007; 384:41-7.1761086010.1016/j.cca.2007.05.015
- Zhu W, Liu M, Wang GC, Che JP, Xu YF, Peng B, et al. Urinary neutrophil gelatinase-associated lipocalin, a biomarker for systemic inflammatory response syndrome in patients with nephrolithiasis. J Surg Res. 2014; 187:237-43.10.1016/j.jss.2013.09.03624239146
- Fahmy N, Sener A, Sabbisetti V, Nott L, Lang RM, Welk BK, et al. Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endo. 2013; 27:1455-62.
- Horuz R, Goktas C, Cetinel CA, Akca O, Aydin H, Ekici ID, et al. Role of TNF-associated cytokines in renal tubular cell apoptosis induced by hyperoxaluria. Urolithiasis. 2013; 41:197-203.10.1007/s00240-013-0559-623595894
- Suen JL, Liu CC, Lin YS, Tsai YF, Juo SH, Chou YH. Urinary chemokines/cytokines are elevated in patients with urolithiasis. Urol Res. 2010; 38:81-7.10.1007/s00240-010-0260-y20204339
- Manoharan M, Schwille PO. Oxypurines, protein, glucose and the functional state of blood vasculature are markers of renal calcium stone-forming processes? Observations in men with idiopathic recurrent calcium urolithiasis. Clin Chem Lab Med. 2002; 40:266-77.12005217
- Pourmand G, Nasseh H, Sarrafnejad A, Mojtahedi A, Mehrsai A, Alamdari DH, et al. Comparison of urinary proteins in calcium stone formers and healthy individuals: a case-control study. Urol Int. 2006; 76: 163-8.1649322010.1159/000090882
- Walton RC, Kavanagh JP, Heywood BR, Rao PN. The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for nonspecific interactions. Biochim Biophys Acta. 2005; 1723:175-83.10.1016/j.bbagen.2005.02.014
- Bergsland KJ, Kelly JK, Coe BJ, Coe FL. Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers. Am J Physiol Renal Physiol. 2006; 291:F530-6.1662217610.1152/ajprenal.00370.2005
- Thongboonkerd V. Proteomics and kidney stone disease. Contrib Nephrol. 2008; 160:142-58.18401167
- Merchant ML, Cummins TD, Wilkey DW, Salyer SA, Powell DW, Klein JB, et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. Am J Physiol Renal Physiol. 2008; 295:F1254-8.10.1152/ajprenal.00134.200818701630
- Parsons CL, Rajasekaran M, Arsanjani AH, Chenoweth M, Stein P. Role of sialic acid in urinary cytoprotective activity of Tamm-Horsfall protein. Urology. 2007; 69:577-81.10.1016/j.urology.2006.12.02617382182
- Viswanathan P, Rimer JD, Kolbach AM, Ward MD, Kleinman J G, Wesson JA. Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein. Urol Res. 2011; 39:269-82.2122923910.1007/s00240-010-0353-7
- Webber D, Radcliffe CM, Royle L, Tobiasen G, Merry AH, Rodgers AL, et al. Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. FEBS. 2006; 273:3024-37.10.1111/j.1742-4658.2006.05314.x
- Jaggi M, Nakagawa Y, Zipperle L, Hess B. Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res. 2007; 35:55-62.1734507710.1007/s00240-007-0083-7
- Gudbjartsson DF, Holm H, Indridason OS, Thorleifsson G, Edvardsson V, Sulem P, et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genetics. 2010; 6:e1001039.2068665110.1371/journal.pgen.1001039